Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update • Total revenue of $73 million in 2Q26, a 92% year-over-year increase – • Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – • Niktimvo™ (axa
How this was made
The 30-second read
Why it matters
Traders can update models using the reported quarterly revenue, product-level net revenue, and prescription growth, and re-rank catalysts around expected 4Q26 Phase 2 topline data for axatilimab in IPF and frontline cGVHD.
Market read
Quantified quarterly performance plus explicit near-term clinical timing provides a fresh basis for positioning ahead of the company’s call and 4Q26 catalysts.
What to watch
The filing includes multiple trial readouts and pipeline expansions, but the most market-moving item may be whether 4Q26 axatilimab topline data meets expectations; any delay or weaker efficacy could offset commercial strength.
Background
This is an SEC Form 8-K (Item 2.02) with 2Q26 financial results and a business update for Syndax Pharmaceuticals.
Ticker impact
Syndax reported 2Q26 revenue of $73M, with Revuforj net revenue $54.7M and Niktimvo net revenue $60.3M, plus pipeline and 4Q26 Phase 2 data expectations.
Likely positive bias for near-term trading as investors price in accelerating commercial annualization and upcoming 4Q26 clinical readouts.
The filing is a primary disclosure (8-K) with quantified quarterly financials, prescription counts, and explicit timing for future Phase 2 topline data.
Market effects
Reinforces demand and durability for menin inhibition in AML and cGVHD, potentially supporting sentiment for hematology oncology peers with similar mechanisms.
Limited, primarily US small/mid-cap biotech sentiment via Nasdaq-listed name.
Modest, as the catalysts are company-specific clinical timelines and quarterly commercial results.
Counterpoint
Revenue growth may be partially driven by post-transplant duration and collaboration accounting, so investors may scrutinize sustainability and margin trajectory beyond prescriptions.
Key entities
- companySyndax Pharmaceuticals
Commercial-stage biopharmaceutical company advancing Revuforj (revumenib) and Niktimvo (axatilimab-csfr).
- productRevuforj (revumenib)
Menin inhibitor with 2Q26 net revenue of $54.7M and ~1,500 prescriptions in the quarter.
- productNiktimvo (axatilimab-csfr)
Asset with 2Q26 net revenue of $60.3M and collaboration revenue of $18.1M, with Phase 2 topline data expected in 4Q26.
